The North America Injection Pen Market size was valued at USD 1,420 Million in 2025, and is projected to reach USD 2,980 Million by 2035, growing at a CAGR of 6.9% from 2024 to 2035. This growth is attributed to increasing prevalence of chronic diseases such as diabetes and multiple sclerosis and the adoption of user-friendly self-administration drug delivery devices.
The economic impact of tariffs on "North America Injection Pen Market".
Market Growth Drivers
Rising Prevalence of Diabetes and Chronic Diseases: The steady increase in diabetes and other chronic conditions in North America is creating high demand for convenient drug delivery methods. According to Novo Nordisk, the incidence of Type 1 and Type 2 diabetes has surged, prompting patients to seek easier and more effective ways to manage their conditions. Injection pens, by offering simplicity, portability, and dose accuracy, have become widely accepted for insulin and GLP-1 administration. Major players like Eli Lilly and Sanofi invest in expanding injection pen offerings to target these patient populations.
Technological Advancements and Product Innovation: Companies such as BD (Becton, Dickinson and Company) and Ypsomed are introducing next-generation digital and smart injection pens that facilitate precise dosing, data connectivity, and patient adherence tracking. These innovations not only improve user compliance but also appeal to healthcare providers by enabling remote monitoring and better control of patient outcomes. The integration of Bluetooth and smartphone app compatibility is strengthening market growth, particularly among younger, tech-savvy patients.
Latest Market Trends
Growth of Smart and Connected Devices: The advancement and adoption of smart injection pens with built-in connectivity features are shaping the market landscape. Devices such as Novo Nordisk’s NovoPen 6 can record dosing history and share data with health apps, supporting improved disease management. Such innovation is facilitating better communication between patients and healthcare professionals in North America, driving further adoption of pen technology.
Sustainable and Eco-Friendly Injection Pens: Companies are focusing on sustainability in product design. For example, Novo Nordisk announced a move to incorporate more recycled materials into its injection pen manufacturing process. Additionally, demand for reusable pens over disposable ones is increasing, as patients and providers become more environmentally conscious. This is pressuring manufacturers across the region, notably BD and Sanofi, to innovate around greener, more cost-efficient devices.
Market Opportunities
Expansion into Home Healthcare Segment: The rising trend of home healthcare services in North America presents a significant opportunity for injection pen manufacturers. Companies like Ypsomed and Sanofi are partnering with home care providers to deliver training and support solutions for patients using injection pens at home rather than in clinical settings.
Focus on Pediatric and Geriatric Populations: There is a growing opportunity for device makers to specifically target pediatric and elderly patients. Companies such as Eli Lilly are exploring ergonomic pen designs and simplified features tailored to these demographics, aiming to improve medication adherence and enhance healthcare outcomes.
North America Injection Pen Market Revenue (USD Million), 2020-2035
The revenue chart illustrates a consistent, upward trajectory for the North America Injection Pen Market. Beginning at USD 790 Million in 2020, the market grows steadily each year, reaching USD 1,420 Million in 2025 and projected to rise significantly to USD 2,980 Million by 2035. Key inflection points include rapid adoption in the mid-2020s, corresponding to rising chronic disease rates and adoption of advanced pen technologies. This trend underscores robust demand and the persistent innovation by manufacturers, signaling strong growth potential over the coming decade.
North America Injection Pen Market Share by Region (%), 2025
The pie chart for 2025 demonstrates that the United States leads the North America Injection Pen Market, commanding a market share of 72%. Canada follows with 19%, while Mexico accounts for 7%. The rest of North America makes up 2% of the market. This distribution reflects the high concentration of chronic disease cases and advanced healthcare system in the US, combined with high adoption of technology-driven health solutions, giving it a dominant position in the region. Canada and Mexico are also seeing increased uptake, driven by local market dynamics and access to innovative devices.
Recent Developments in North America Injection Pen Market (Past 6 Months)
In March 2024, Novo Nordisk launched its NovoPen Echo Plus in the US, a new smart insulin pen with dose memory and connectivity features, aiming to improve treatment adherence among pediatric and adolescent diabetes patients. The launch is part of their broader digital health strategy, integrating pen data with mobile apps to support both patients and clinicians.
In February 2024, BD announced FDA clearance for its new BD Autopen Pro, a reusable injection pen designed for biologic drugs beyond insulin, such as growth hormones and fertility treatments. The device features variable dosing, enhanced grip, and compatibility with digital health platforms, reflecting BD’s commitment to device innovation and patient-centric solutions.
In January 2024, Ypsomed partnered with a leading US pharmacy chain to introduce the YpsoMate Smart device system, a connected, single-use injection pen coupled with app-based digital support and reminders. This collaboration aims to increase patient engagement, medication adherence, and expand Ypsomed’s North American footprint through integrated healthcare solutions.
Press Releases